News Release

<< Back
Life Epigenetics CEO Jon Sabes to Present at ReFocus Conference 2019 on March 11
March 7, 2019 at 4:55 PM EST

MINNEAPOLIS, March 07, 2019 (GLOBE NEWSWIRE) -- Life Epigenetics, a biotechnology company that discovers, quantifies and commercializes epigenetic signatures for use in the longevity, clinical research, pharmaceutical, and nutraceutical markets, announced that its Chief Executive Officer Jon Sabes will present at ReFocus Conference 2019 in Las Vegas on Monday, March 11.

Jon Sabes
Life Epigenetics CEO Jon Sabes

Life Epigenetics
Life Epigenetics

Sabes will be on a panel of experts at the global reinsurance conference that is sponsored by the American Council of Life Insurers and the Society of Actuaries. The panel, called “Maximizing the Value of Your Inforce Block,” explores the use of new processes and technologies in the longevity market that includes life insurance, annuities and pensions. The panel will be held from 2:00 to 3:15 p.m. PDT.

In October 2018, Life Epigenetics initiated a research study that included gathering biological samples, prescription data and medical histories from 1,300 individuals to build machine-learned epigenetic signatures of aging, wellness, mortality, clinical chemistries, chronic disease states, and the use of tobacco, alcohol, drugs of abuse, and underwriting risk classifications. The company expects to complete its study in the second quarter.

“We are excited to have the opportunity to present how we are creating a more precise method of underwriting longevity products,” Sabes said. “Our research is giving us insights into the epigenetic signatures that will enable consumers to enhance their well-being and better plan for their financial future.”

To view Sabes’ presentation, go to page 21 at the panel’s webpage.

About Life Epigenetics and GWG Holdings, Inc.

GWG Holdings, Inc. (Nasdaq: GWGH), the parent company of GWG Life, Life Epigenetics and YouSurance, is a leading investor in longevity insurance assets. GWG Life provides value to owners of illiquid life insurance products across America, delivering more than $564 million to consumers since 2006. GWG Life owns longevity risk alternative assets in the form of a portfolio of life insurance policies with $1.96 billion in face value of benefits as of September 30, 2018. Life Epigenetics is commercializing epigenetic technology for the longevity industry and beyond. YouSurance is working to offer consumers  access to advanced epigenetic technology to reduce the cost of life insurance.

For more information about GWG Holdings, email or visit

For more information about Life Epigenetics visit

For more information about YouSurance visit

Media Contact:
Dan Callahan
Director of Communication
Life Epigenetics
(612) 746-1935

A photo accompanying this announcement is available at

Source: GWG Holdings, Inc.